# Circio Schedules November 27 Webcast Covering Heart Gene Therapy and Solid Biosciences Collaboration

> Circio will host a live webcast on November 27, 2026, covering its heart gene therapy program, the Solid Biosciences collaboration and new circVec data.

- Published: 2026-11-20T08:32:44+00:00
- Section: Business
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-20/circio-november-27-webcast-heart-gene-therapy
- Source: [TradingView](https://www.tradingview.com/news/modular_finance:ba9db18963f67:0-circio-invites-to-live-webcast-on-27-november-2026-at-10-00-am-cet/)

## Key takeaways

- Circio will host a live webcast at 10:00am CET on November 27, 2026, with CEO Dr. Erik D Wiklund and CTO Dr. Thomas B Hansen presenting.
- The webcast covers the heart gene therapy program, the collaboration with Solid Biosciences and new in vivo proof-of-concept data for circVec in next-generation AAV capsids.
- Circio completed a NOK 300 million financing in June 2026, extending its cash runway to the end of 2030.

Circio Holding ASA will host a live webcast at 10:00am CET on November 27, 2026, covering its heart gene therapy program, its collaboration with Solid Biosciences and new in vivo proof-of-concept data for circVec in next-generation AAV capsids. [TradingView](https://www.tradingview.com/news/modular_finance:ba9db18963f67:0-circio-invites-to-live-webcast-on-27-november-2026-at-10-00-am-cet/) published the invitation on November 20, 2026.

## What Circio Will Present on November 27

[Circio](https://akta.pro/company-profiles/0005hep/circio) is a Norwegian biotechnology company developing circular RNA expression technology for gene and cell therapy. CEO Dr. Erik D Wiklund will give an overview of business development activities, including the recently announced collaboration with [Solid Biosciences](https://akta.pro/company-profiles/0000bwa/solid-biosciences). CTO Dr. Thomas B Hansen will present the latest circVec pre-clinical gene therapy results.

The results cover the heart program, new in vivo proof-of-concept data for circVec in next-generation AAV capsids, and a summary of the oral presentation and two posters delivered at ESGCT 2026. Presentation materials will be published ahead of the webcast on November 27, 2026. The webcast will be held in English, and questions can be submitted in advance by email to Wiklund or directly during the live webcast. A recording will be made available on the Circio webpage.

## Circio's Financing and Patent Record

Circio completed a NOK 300 million (approximately EUR 27 million) financing in June 2026 through warrant exercises and an underwritten private placement, extending its cash runway to the end of 2030, according to akta.pro [company records](https://akta.pro/company-data). The same records show Circio filed an EPO patent application on May 21, 2026 covering aspects of the circVec platform for enhanced gene and cell therapy.

## Circio's Path to the Solid Biosciences Deal

On November 10, 2026, Circio and Solid Biosciences announced a research collaboration to evaluate Circio's circVec platform with Solid's POLARIS-101 AAV capsid for genetic heart disease, Investegate reported. In Vivo reported on November 3, 2026 that Circio pivoted from oncolytic virus and cancer vaccine programs to circular RNA three and a half years ago. On September 22, 2026, Circio registered a share capital increase following a private placement of 16,865,000 new shares, The future of trading reported.

## Circio's November 27 Webcast Details

The webcast takes place at 10:00am CET on November 27, 2026, and presentation materials will be published ahead of it that day.

## Companies in this story

- [Circio company profile](https://akta.pro/company-profiles/0005hep/circio) · website: https://www.circio.com
- [Solid Biosciences company profile](https://akta.pro/company-profiles/0000bwa/solid-biosciences) · website: http://solidbio.com

---
News for Agent · https://newsforagent.com/llms.txt
